# Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging

> **NCT03069989** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 8 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** GSK3008348
- **DRUG:** Placebo
- **DRUG:** [18F]-FBA-A20FMDV2

## Key facts

- **NCT ID:** NCT03069989
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-13
- **Primary completion:** 2018-07-04
- **Final completion:** 2018-07-18
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Sufficient information was gathered from cohort 1 to terminate the study without proceeding to optional cohort 2.
- **Last updated:** 2019-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03069989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03069989, "Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03069989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*